Holen Sie sich die Stockscreener-App
7.53
1.31%
-0.10
Handel nachbörslich:
7.33
-0.20
-2.66%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt AVXL?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$7.63
Offen:
$7.5
24-Stunden-Volumen:
841.74K
Relative Volume:
0.85
Marktkapitalisierung:
$642.84M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-43.16M
KGV:
-13.69
EPS:
-0.55
Netto-Cashflow:
$-29.31M
1W Leistung:
+0.00%
1M Leistung:
-21.81%
6M Leistung:
-20.40%
1J Leistung:
+81.88%
1-Tages-Spanne:
$7.31
$7.62
1-Wochen-Bereich:
$7.26
$7.81
52-Wochen-Spanne:
$3.51
$14.44
Anavex Life Sciences Corporation Stock (AVXL) Company Profile
Firmenname
Anavex Life Sciences Corporation
Sektor
Branche
Telefon
844-689-3939
Adresse
630 5TH AVENUE, NEW YORK
Vergleichen Sie AVXL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AVXL
Anavex Life Sciences Corporation
|
7.53 | 642.85M | 0 | -43.16M | -29.31M | -0.55 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Anavex Life Sciences Corporation Stock (AVXL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-12-06 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-23 | Eingeleitet | Berenberg | Buy |
| 2021-09-23 | Eingeleitet | BTIG Research | Buy |
| 2020-12-16 | Bestätigt | H.C. Wainwright | Buy |
| 2020-09-28 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2020-02-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-06-18 | Eingeleitet | Janney | Buy |
| 2018-05-16 | Fortgesetzt | Maxim Group | Buy |
| 2018-03-08 | Eingeleitet | ROTH Capital | Buy |
| 2018-02-13 | Bestätigt | Maxim Group | Buy |
| 2017-09-29 | Fortgesetzt | Noble Financial | Buy |
| 2017-02-07 | Eingeleitet | Noble Financial | Buy |
| 2016-03-29 | Eingeleitet | FBR Capital | Outperform |
Alle ansehen
Anavex Life Sciences Corporation Aktie (AVXL) Neueste Nachrichten
Deutsche Bank AG Has $693,000 Stock Position in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
D. E. Shaw & Co. Inc. Purchases Shares of 105,130 Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Northern Trust Corp Raises Stake in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
The Manufacturers Life Insurance Company Has $298,000 Holdings in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
HC Wainwright Issues Positive Forecast for AVXL Earnings - Defense World
Anavex Life Sciences Corp.'s (NASDAQ:AVXL) largest shareholders are individual investors with 60% ownership, institutions own 37% - Yahoo Finance
Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Sold by Price T Rowe Associates Inc. MD - Defense World
Tower Research Capital LLC TRC Buys 1,708 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Anavex Life Sciences Corp (AVXL) Q2 2025 Earnings Call Highlight - GuruFocus
Anavex Life Sciences Corp (AVXL) Q2 2025 Earnings Call Highlights: Promising Alzheimer's Data ... - Yahoo Finance
Anavex Life Sciences Corp. (NASDAQ:AVXL) Q2 2025 Earnings Call Transcript - Insider Monkey
Anavex Life Sciences to Participate at Upcoming Healthcare Confe - GuruFocus
Anavex Life Sciences to Participate at Upcoming Healthcare Conferences | AVXL Stock News - GuruFocus
Anavex Life Sciences to Participate at Upcoming Healthcare Conferences - The Manila Times
Anavex Brings Alzheimer's and Parkinson's Drug Updates to Prestigious Wainwright Healthcare Conferences - Stock Titan
Anavex Life Sciences: Fiscal Q2 Earnings Snapshot - CT Insider
Anavex Life Sciences Reports Q2 2025 Financial Results - TipRanks
Raymond James Financial Inc. Makes New $167,000 Investment in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Earnings call transcript: Anavex Life Sciences Q2 2025 reports net loss, stock rises - Investing.com Nigeria
Anavex Life Sciences (AVXL) Q2 Earnings Exceed Expectations - GuruFocus
Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financia - GuruFocus
Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update - The Manila Times
Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update | AVXL Stock News - GuruFocus
Anavex Life Sciences Corp. Reports Q2 Fiscal 2025 Financial Results and Updates on Clinical Developments - Nasdaq
Anavex Life Sciences Corp. Q2 Loss Beats Estimates - Nasdaq
Anavex Life Sciences Corp expected to post a loss of 15 cents a shareEarnings Preview - TradingView
Is Anavex Life Sciences Corp. (AVXL) the Low Risk High Reward Stock Set to Triple by 2030? - Insider Monkey
Closing Bell Recap: Anavex Life Sciences Corporation (AVXL) Ends at 8.91, Reflecting a -4.81 Downturn - DWinneX
Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Fina - GuruFocus
Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025 | AVXL Stock News - GuruFocus
Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025 - The Manila Times
Anavex Life Sciences Corp. to Announce Second Fiscal Quarter Financial Results on May 13, 2025 - Nasdaq
Anavex Life Sciences Earnings Preview: Key Updates Coming on Alzheimer's and Rare Disease Programs - Stock Titan
Envestnet Asset Management Inc. Purchases 20,771 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Head-To-Head Comparison: Anavex Life Sciences (NASDAQ:AVXL) vs. Sorrento Therapeutics (OTCMKTS:SRNEQ) - Defense World
Taking on analysts’ expectations and winning: Anavex Life Sciences Corporation (AVXL) - Sete News
Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Sold by JPMorgan Chase & Co. - Defense World
Anavex Life Sciences' Schizophrenia Clinical Study Completes Enrollment - marketscreener.com
Anavex Life Sciences Corporation (AVXL) is an excellent investment, but the stock is overvalued/undervalued right now - uspostnews.com
Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia - The Manila Times
Anavex Life Sciences Corporation [AVXL] Records 50-Day SMA of $8.86 - knoxdaily.com
Anavex Life Sciences to Participate in The Citizens Life Sciences Conference | AVXL Stock News - GuruFocus
Anavex Life Sciences to Participate in The Citizens Life Sciences Conference - The Manila Times
Anavex Showcases Breakthrough CNS Drug Portfolio: CEO Details Multiple Disease Targets at Citizens Conference - Stock Titan
Wells Fargo & Company MN Decreases Position in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Anavex Life Sciences Corp. to Present at The Citizens Life Sciences Conference in New York, May 2025 - Nasdaq
Press Release Distribution & PR Platform - ACCESS Newswire
Finanzdaten der Anavex Life Sciences Corporation-Aktie (AVXL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):